Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma
Journal
Asia-Pacific Journal of Clinical Oncology
Journal Volume
6
Journal Issue
2
Pages
80-88
Date Issued
2010
Author(s)
Abstract
Treatment of advanced hepatocellular carcinoma (HCC) remains a significant problem for clinicians. Sorafenib, the only approved agent, improves survival rate, but is associated with a low tumor response rate. Alternative approaches for the treatment of advanced HCC are urgently needed. Hepatic arterial infusion of chemotherapy (HAIC) is a promising modality for the treatment of advanced HCC. Since its introduction, there have been improvements in implantable pumps, in catheter implantation and in the convenience and safety of HAIC in general. Numerous clinical studies have shown that HAIC provides moderate therapeutic efficacy with substantially favorable toxicity profiles in selected patient groups with advanced HCC. However, the lack of large randomized studies means that HAIC is not yet a well-established treatment for advanced HCC. We believe there is an urgent need for the further investigation of HAIC for the treatment of advanced HCC. ? 2010 Blackwell Publishing Asia Pty Ltd.
SDGs
Other Subjects
alpha interferon; anthracycline; carboplatin; cisplatin; doxorubicin; epirubicin; etoposide; fluorouracil; folinate calcium; folinic acid; macrosalb tc 99m; mitomycin C; peginterferon alpha; sorafenib; antineoplastic agent; advanced cancer; angiography; anorexia; artery dissection; artery occlusion; artery puncture; artificial embolism; axillary artery; bone marrow suppression; cancer combination chemotherapy; cancer survival; catheter complication; catheter infection; catheterization; celiac artery; daily life activity; depression; diarrhea; drug dose escalation; drug efficacy; drug infusion; drug safety; femoral artery; first pass effect; flow rate; fluoroscopy; gastritis; gastroduodenal artery; hematoma; hepatic artery; human; hypertransaminasemia; infection; infusion pump; laparotomy; leukopenia; liver cell carcinoma; liver cirrhosis; liver dysfunction; liver function; liver metastasis; minipump; nausea; neutropenia; patient selection; peptic ulcer; portal vein thrombosis; priority journal; proper hepatic artery; review; shunting; subclavian artery; superior mesenteric artery; survival rate; systemic therapy; thrombocytopenia; treatment response; Carcinoma, Hepatocellular; intraarterial drug administration; Liver Neoplasms; pathology; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms
Publisher
Blackwell Publishing Ltd
Type
review